1. Pseudomonas aeruginosa 136 (15.4%) 70 (19.2%) 66 (12.7%) 0.009
Table 1. Seven main organisms isolated from SSI according to the type of SSI
No. of strains (%)
P-value
Total
Incisional
SSI
Organ space SSI
Enterobacteriaceae*
304 (34.4%)
96 (26.3%)
208 (40.2%)
<0.001
Pseudomonas aeruginosa
136 (15.4%)
70 (19.2%)
66 (12.7%)
0.009
Staphylococcus aureus [MRSA]
160 (18.1%)
[86, 9.7%]
82 (22.5%)
[40, 11.0%]
78 (15.1%)
[46, 8.9%]
0.005
[0.305]
Enterococcus faecalis
170 (19.3%)
73 (20.0%)
97 (18.7%)
0.636
Bacteroides fragilis group
113 (12.8%)
44 (12.1%)
69 (13.3%)
0.579
883 (100.0%)
365 (100.0%)
518 (100.0%) ―
*:E. coli (n=152), E. cloacae (n=96), K. pneumoniae (n=56)

2. Table 2. Main organisms isolated from surgical site infection (SSI) according to the type of procedure in the surveillance conducted between and 2015
Main organisms isolated from SSI
Type of procedure
Surgery for lower intestinal tract
Surgery for stomach and esophagus
Surgery for hepatobiliary-pancreas
Other abdominal surgery
Procedures except for abdominal surgery
Total
Enterobacteriaceae
148 38 97 6 15
304 (34.4%)
Pseudomonas aeruginosa 65 26 33 4 8
136 (15.4%)
Staphylococcus aureus [MRSA]
55[35]
　　14 [6]
　　46 [24]
4 [2]
42 [20]
160 (18.1%)
[86, 9.7%]
Enterococcus faecalis 90 61 2
170 (19.3%)
Bacteroides fragilis group 91 13 1
113 (12.8%)
446
101
250 17 69
883 (100%)

3. ESBL producing organisms CPE* CRE** except for CPE
Table 3. Comparison of the incidence of antibiotic resistant Enterobacteriaceae between 2010 and 2014–15
ESBL producing organisms
CPE*
CRE** except for CPE
2010
Echerichia coli
9/95
(9.5%)
35/152 (23.0%)
Klebsiella pneumoniae
0/53(0%)
6/56 (10.7%) 1
(1.9%)
1 (1.8%)
Enterobacter cloacae
0/58(0%)
0/96 (0%)
(1.7%)
1 (1.0%) 12
(20.7%)
25 (26.0%)
Total
11/206 (5.3%)
41/304 (13.5%) 2
(1.0%)
2 (0.7%)
(5.8%)
25 (8.2%)
　E. coli (n=152)
K. pneumoniae (n=56)
E. cloacae (n=95)
*: carbapenemase producing Enterobacteriaceae, ***: notification criteria of carbapenem resistant Enterobacteriaceae (CRE) defined by Ministry of Health, labour and Welfare in Japan

4. Geometric standard deviation
Table 4. Change of antibiotic susceptibility distribution in MRSA between 2010 and
Anti-microbial agent
year
MIC (μg/mL)
Geometric mean MIC
(μg/mL)
Geometric standard deviation
95% CI
P-value
≤0.063
0.125
0.25
0.5 1 2 4 8 16
≥32
VCM
2010 91 10
1.055
1.261
-0.177, 0.585
0.292 19 65
0.851
1.392
TEIC 3 44 39 15
0.823
1.853
-0.533,
0.530
0.996 36 6
0.824
1.836
ABK 57 35
0.659
1.676
-0.331,
0.665
0.510 23 43 1　
0.492
1.790
LZD 25 74
1.736
1.407
-0.502, 0.284
0.586 9 75
1.845
1.309
DAP 56
0.352
1.490
-0.460,
0.417
0.922 40
0.374
1.559
TGC
Not performed － 27 13 18 28
0.365
2.367
Shaded column indicate the susceptive range; 95% CI: 95% confidence interval

5. Table 5. Comparison of antibiotic susceptibility distribution in Gram-negative organisms between the surveillance studies conducted in 2010 and 2014–15
Antimicrobial agents
Susceptible rate (%)
E. coli
K. pneumoniae
E. cloacae
P. aeruginosa
2010
(n=95)
2014–15
(n=152)
(n=53)
(n=56)
(n=58)
(n=108)
(n=136)
SBT/ABPC
56.8
69.7
88.7 －
TAZ/PIPC*
95.8
95.4
96.2
98.2
81.0
83.3
92.6
93.4
CEZ
52.6
63.2
81.1
83.9
CMZ
97.4
94.3
94.6
0.0 －　
CAZ
89.5
92.1
98.1
96.4
74.1
68.8
89.8
94.1
CFPM
96.8
80.3
100.0
92.9
92.7
91.7
95.6
MEPM
97.9
93.5
91.9
IPM
71.9
88.0
84.6
AZT
87.4
82.2
77.6
86.1
89.7 GM
90.5
99.3
CPFX
73.7
73.0
91.1
93.8
*: Susceptibility testing with a fixed concentration of 4 µg/mL TAZ

6. Geometric standard deviation
Table 6. Antibiotic susceptibility distribution in extended-spectrum β-lactamase-producing Enterobacteriaceae
Anti-microbial agent
MIC (μg/mL), n=41
Susceptibility rate
Geometric mean MIC
(μg/mL)
Geometric standard deviation
≤0.063
0.125
0.25
0.5 1 2 4 8 16 32 64
128
≥ 256
MEPM 38
100%
0.065
1.165
TAZ/PIPC* 14 3 1　 -
9.514
2.857
TAZ/PIPC** 5 20
92.5%
2.979
3.132
CMZ
1.741***
3.972
CFX 11 15 6
80.0 %
6.169
3.603
FMOX 27 －
0.149****
7.271 GM
75.0%
1.5516
6.785
CPFX 13 7
27.5%
8.877
12.661
STFX 9 17
0.500*****
3.964
n=41, E. coli 35株, K. pneumoniae 6株.
1例 メタロβラクタマーゼ産生
MEPM 0.071
TAZ/PIPC 9.514
CMZ 1.932
FMOX 0.169
GM 1.569
CPFX 7.601
Shaded column indicate the susceptive rang; one strain that produced carbapenemase was excluded. *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used; ***; vs. CFX, P<0.001; ****: vs. CFX, p<0.001, CMZ, P=0.228; *****: vs. CPFX, P<0.001

7. No. of Antibiotic resistant organisms in P. aeruginosa*
Table 7.Comparison of isolation rates for antibiotic-resistant Pseudomonas aeruginosa between the surveillance studies conducted in 2010 and 2014–2015
　Antibiotic resistant organisms in P. aeruginosa*
No. of Antibiotic resistant organisms in P. aeruginosa*
2010, n=108
2014–2015, n=136
Resistance to at least one class of antibiotics
12 (11.1%)
12 (8.8%)
Resistance to at least two classes of antibiotics
6 (5.6%)
6 (4.4%)
Resistance to at least three class of antibiotics
2 (1.9%)
4 (2.9%)
*: P.aeruginosa resistant to any of the following: MEPM; TAZ/PIPC; CFPM; CPFX and GM

8. Geometric standard deviation
Table 8.Antibiotic susceptibility distribution for Bacteroides fragilis group species
Anti-microbial agent
MIC (μg/mL), n=113
Susceptible rate
Geometric mean MIC
(μg/mL)
Geometric standard deviation
≤0.063
0.125
0.25
0.5 1 2 4 8 16 32 64
128
≥256
SBT/ABPC 13 21 15 17 23 18
79.6%
3.452
3.602
TAZ/PIPC*
1 0 22 31 12 3 －
7.297
3.139
TAZ/PIPC ** 6 20 9 11 5
97.3%
1.791
6.865
CMZ 10 14 28 7
49.6%
21.347
2.814
CFX
66.4%
16.000***
2.770
FMOX
10.100****
9.157
MEPM
94.7%
0.462
4.196
CPFX 19 33
21.743
3.286
MFLX 26
61.9%
2.360*****
3.807
STFX 29
0.276******
3.451
CLDM 53
46.9%
10.543
24.140
TGC 35 27
0.384
2.762
MNZ 57 38
100%
1.152
1.785
Shaded column indicate the susceptive range; MIC: minimum inhibitory concentration; *: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used; ***: vs. CMZ, P<0.001; ****: vs. CMZ, CFX, P<0.001; *****: vs. CPFX, P<0.001; ******: vs. CPFX, MFLX, P<0.001

9. Table 9. Comparison of susceptibility rates for Bacteroides fragilis and non-fragilis Bacteroides species identified in the surveillance study conducted in 2014–15
Anti-microbial agent
Susceptible rate
P-value
Bacteroides fragils
(n=53)
Non-fragilis Bacteroides
(n=60)
Bacteroides thetaiotaomicron (n=26)
Other non-fragilis Bacteroides
(n=34)
SBT/ABPC
88.7
71.7
0.045
73.1
70.6
0.832
TAZ/PIPC*
94.3%
100% 　
0.200
100% ―
CMZ
79.2%　
23.3%
<0.001
3.8%
38.2%
0.005
CFX
86.8%　
48.3%
19.2%
70.6%
MEPM
88.7%
0.024
MFLX
67.9%
56.7% 　
0.219
61.5%
52.9%
0.505
CLDM
60.4%
35.0%
0.007
47.1%
0.049
TGC 　―
0.950
MNZ
100%　
*: a fixed concentration of 4 µg/mL TAZ was used

10. Electronic data Supplementary Table 1
Electronic data Supplementary Table 1. Antibiotic susceptibility rates for methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and Enterococcus faecalis
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
MSSA　(74)
MPIPC
0.25
0.5
100.0%
0.0%
ABPC 2
≤0.06-8 ―
SBT/ABPC 1
≤0.06-2
PIPC 4
0.5-8
TAZ/PIPC*
0.5-4
TAZ/PIPC**
CEZ
CAZ 8
4-16
CFPM
1-8
CMZ
0.25-2
CFX
2-4
FMOX
IPM
≤0.06 ≤
PAPM
0.125
MEPM ≤
BIPM
DRPM
CPFX 16
0.125-≥256
81.1%
2.7%
16.2%
LVFX
≤0.06-≥256
83.8%
PZFX
MFLX ≤
1.3%
14.9%
STFX ≤ GM 32
AMK
1-64
98.6%
1.4%
ABK EM
≥256
0.25-≥256
82.4%
CLDM
97.3%
MINO
TGC
VCM
0.5-1
TEIC
DAP
LZD
1-4 ST
0.063
RFP

11. Electronic data Supplementary Table 1. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
MRSA　(86)
MPIPC
128
≥256
1-≥256 ―
CFX 64
0.125-≥256
IPM 2 32
<0.06-≥128
ABK
0.5 1 EM
0.25-≥256
11.6%
0.0%
88.4%
CLDM
27.9%
1.2%
70.9%
MINO 8 16 ≤
41.9%
8.1%
50.0%
TGC
VCM
0.25-2
100.0%
TEIC
DAP
LZD
0.5-4 ST
0.063
0.125
REF
≤0.06
≤0.06-4
98.8%

12. Electronic data Supplementary Table 1. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
E. faecalis　(170)
ABPC 1 2
0.5-8
100.0%
0.0%
PIPC 4
2-32 ―
TAZ/PIPC*
TAZ/PIPC**
IPM
0.25-4
PAPM
0.5-4
MEPM 8
1-16
BIPM
DRPM
1-8
CPFX
75.9%
14.7%
9.4%
LVFX
0.5-≥256
90.6%
0.6%
8.8%
PZFX
1-≥256
MFLX
0.5
STFX
0.125
≤0.06-4
TGC
0.25 ≤
VCM
0.5-2
TEIC
DAP
0.25-8
98.8%
1.2%
LZD
1-4
88.2%
11.8%
*: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used

13. Electronic data Supplementary Table 2
Electronic data Supplementary Table 2. Antibiotic susceptibility of Enterobacteriaceae species
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
E. coli　(152)
ABPC 4
≥256
1-≥256
55.3%
1.9%
42.8%
SBT/ABPC 32
1-≥128
69.7%
16.5%
13.8%
PIPC 2
0.5-≥256
61.2%
4.6%
34.2%
TAZ/PIPC* 16 ≤ ―
TAZ/PIPC**
95.4%
3.3%
1.3%
CEZ 1
≤0.06-≥256
63.2%
3.9%
32.9%
CAZ
0.125
≤0.06-≥128
92.1%
2.0%
5.9%
CFPM
≤0.06 8
80.3%
13.1%
6.6%
CMZ
0.5
97.4%
0.6%
CFX
89.5%
FMOX
0.25
S/C ≤
IPM
≤0.06-1
100.0%
0.0%
PAPM ≤
MEPM ≤
BIPM
DRPM
AZT
82.2%
11.2%
CPFX 64
73.0%
27.0%
LVFX
25.7%
PZFX ≤
MFLX
STFX
≤0.06-4 GM
9.2%
AMK
1-32
99.3%
0.7%
TGC
FOM

14. Electronic data Supplementary Table 2. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
K. pneumoniae　(56)
PIPC 4
≥256
1-≥256
83.9%
1.8%
14.3%
TAZ/PIPC* 16 ≤
TAZ/PIPC** 2 8
0.5-32
98.2%
0.0%
CEZ 1
≤0.06-≥256
16.1%
CAZ
0.125
0.5
96.4%
3.6%
CFPM
≤0.06 ≤
92.9%
3.5%
CMZ
94.6%
CFX
91.1%
5.4%
FMOX ―
S/C ≤
IPM
0.25
PAPM
≤0.06-4
MEPM
≤0.06-2
BIPM
DRPM
AZT ≤
CPFX
LVFX
PZFX
≤0.06-8
MFLX
STFX GM
AMK
0.5-8
100.0%
TGC
0.25-4
FOM 32
2-≥256

15. Electronic data Supplementary Table 2. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
E. cloacae　(96)
PIPC 4
128
≤0.06-≥256
76.0%
9.4%
14.6%
TAZ/PIPC* 64 ≤ ―
TAZ/PIPC** 2
83.3%
8.4%
8.3%
CAZ
0.5
0.125-≥128
68.8%
4.1%
27.1%
CFPM
≤0.06 1 ≤
92.7%
4.2%
3.1%
S/C 16
IPM
0.25-4
71.9%
1.0%
PAPM
MEPM
0.125
≤0.06-2
97.9%
2.1%
0.0%
BIPM
0.25
DRPM
≤0.06-4
1.1%
AZT 32
24.0%
CPFX ≤
93.8%
2.0%
LVFX
94.8%
PZFX
≤0.06-8
MFLX ≤
STFX GM
0.25-≥256
AMK
0.5-64
99.0%
TGC
0.25-8
FOM
1-≥256
89.6%
6.2%
*: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used

16. Electronic data Supplementary Table 3
Electronic data Supplementary Table 3. Antibiotic susceptibility of Pseudomonas aeruginosa
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
P. aeruginosa　(136)
PIPC 4 16
≤0.06-≥256
91.9%
5.2%
2.9%
TAZ/PIPC* ―
TAZ/PIPC**
93.4%
3.7%
CAZ 2 ≤
94.1%
3.0%
CFPM
95.6%
0.7%
S/C
IPM 8
84.6%
12.5%
PAPM ≤
MEPM
0.5
5.1%
BIPM ≤
DRPM
0.25
92.6%
4.5%
AZT
89.7%
CPFX 1
1.5%
5.9%
LVFX
0.8%
6.6%
PZFX
MFLX
STFX
0.125
≤0.06-4 GM
99.3%
0.0%
AMK
0.25-8
100.0%
ABK
FOM 32
128
2-≥256
*: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used

17. Electronic data Supplementary Table 4
Electronic data Supplementary Table 4. Antibiotic susceptibility of Bacteroides fragilis group species
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
B. fragilis　(53)
ABPC
128
≥256
0.5-≥256
1.9%
0.0%
98.1%
SBT/ABPC 2 16
0.25-≥128 ―
PIPC 32
1-≥256
50.9%
9.5%
39.6%
TAZ/PIPC* 4
TAZ/PIPC**
0.5
≤0.06-≥256
94.3%
5.7%
CAZ 64
≥128
2-≥128
CFPM
2-≥256
CMZ 8
4-128
79.2%
11.4%
9.4%
CFX
4-≥256
86.8%
3.8%
FMOX
0.25-≥256
S/C
IPM
0.25
≤0.06-≥128
PAPM
MEPM
88.7%
7.5%
BIPM 1
0.125-≥256
DRPM
0.125-≥128
11.3%
CPFX
LVFX
1-128
PZFX
MFLX
67.9%
7.6%
24.5%
STFX
0.125
≤0.06-4
CLDM
60.4%
MINO ≤
TGC
MNZ
0.25-4
100.0%

18. Electronic data Supplementary Table 4. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
B. thetaiotaomicron　(26)
ABPC
≥256
8-≥256
0.0%
100.0%
SBT/ABPC 8 16
1-16 ―
PIPC
16-≥256
30.8%
3.8%
65.4%
TAZ/PIPC* 32
8-32
TAZ/PIPC**
0.5-32
CAZ
≥128
CFPM
CMZ 64
128
16-128
23.1%
73.1%
CFX
19.2%
53.9%
26.9%
FMOX
4-≥256
S/C
2-16
IPM
0.5 2
96.2%
PAPM 4
MEPM
BIPM
0.25-4
DRPM
CPFX
LVFX
4-128
PZFX
MFLX
1-32
61.5%
27.0%
11.5%
STFX
CLDM
0.25-≥256
11.6%
69.2%
MINO
≤0.06-4
TGC
0.25
≤0.06-2
MNZ
0.5-4

19. Electronic data Supplementary Table 4. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
other Bacteroides　 spp. (34)
ABPC
≥256
4-≥256
　0.0%
0.0%
100.0%　
SBT/ABPC 8 16
1-32 ―
PIPC
128
32.4%
11.7%
55.9%
TAZ/PIPC* 32
2-64
TAZ/PIPC** 4 ≤
100.0%
CAZ
≥128
16-≥128
CFPM
8-≥256
CMZ 64
4-128
38.2%
29.4%
CFX
2-128
70.6%
20.6%
8.8%
FMOX
0.5-≥256
S/C
2-16
IPM
0.5 2
PAPM 1
≤0.06-8
MEPM
BIPM
DRPM
0.25-2
CPFX
LVFX
1-128
PZFX
2-≥256
MFLX
52.9%
8.9%
STFX
0.25
≤0.06-4
CLDM
≤0.06-≥256
47.1%
5.8%
MINO
TGC
≤0.06-2
MNZ
*: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used

20. Electronic supplementary Table 5
Electronic supplementary Table 5. Antibiotic susceptibility in organisms isolated from organ/space SSI in the surveillance conducted between 2014 and 2015
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
E. coli (111)
SBT/ABPC 4 32
69.4%
17.1%
13.5%
TAZ/PIPC* 2 16 ―
TAZ/PIPC**
95.5%
2.7%
1.8%
CFPM
≤0.06 8
80.2%
6.3%
MEPM
100.0%
0.0% GM
0.5
91.0%
0.9%
8.1%
CPFX
72.1%
27.9%
LVFX
0.125
26.1%
PZFX
MFLX
STFX 1

21. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
K. pneumonia (43)
TAZ/PIPC* 4 8
TAZ/PIPC** 2
97.7%
2.3%
0.0%
CEZ 1
≥128
83.7%
16.3%
CMZ
0.5
CAZ
0.125
95.3%
4.7%
CFPM
≤0.06
90.7%
MEPM
IPM
0.25
AZT GM
CPFX
LVFX

22. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
E.cloacae (54)
TAZ/PIPC* 4 64
TAZ/PIPC**
128
77.8%
7.4%
14.8%
CMZ
≥128
0.0%
1.9%
98.1%
CAZ
0.5
66.7%
5.6%
27.8%
CFPM
≤0.06
88.9%
3.7%
MEPM
0.125
IPM 1 2
79.6%
20.4%
AZT 32
72.2%
25.9% GM
0.25
100.0%
CPFX
LVFX
90.7%

23. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
P. aeruginosa (66)
TAZ/PIPC* 4 16 ―
TAZ/PIPC**
90.9%
6.1%
3.0%
CAZ 2
92.4%
4.6%
CFPM
95.5%
0.0%
4.5%
IPM
78.8%
16.7%
PAPM 8 32 　― ―　
MEPM
0.5
89.4%
CPFX
0.25 1
1.5%
7.6%
LVFX
9.1%
PZFX
MFLX
STFX
0.125 GM
98.5%
AMK
100.0%

24. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
MSSA　(32)
ABPC
0.25 2
≤0.06-2 -
SBT/ABPC
0.5
PIPC 1 4
0.5-8
TAZ/PIPC **
0.5-2
CEZ
CAZ 8
4-16
CFPM
1-4
CMZ
1-2
CFX
2-4
100.0%
0.0%
FMOX
IPM
≤0.06 ≤
MEPM
0.125 ≤
CPFX
93.8%
6.3%
LVFX ≤
MFLX
≤0.06-4 GM
90.6%
3.1%
AMK
1-64
96.9%
ABK EM
≥128
0.25-≥128
81.3%
18.8%
CLDM
MINO
TGC
VCM
0.5-1
TEIC
DAP
LZD ST
0.06
RFP

25. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC50
MIC90
Range
Susceptible
Intermediate
Resistant
MRSA　(46)
ABK
0.5 1
0.25-8 -
CLDM
≥128
0.125-≥128
21.7%
2.2%
76.1%
MINO 16 ≤
32.6%
8.7%
58.7%
TGC
VCM
0.25-2
100.0%
0.0%
TEIC 2
0.5-8
DAP
0.25-1
LZD
1-4 ST
0.063
0.125
REF
≤0.06
≤0.06-4
97.8%

26. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
E. faecalis (97)
ABPC 1 2
100.0%
0.0%
PIPC 4 ―
IPM
LZD
90.7%
9.3%
CPFX 32
76.3%
11.3%
12.4%
LVFX
87.6%
1.1%
MFLX
0.5 8
STFX
0.125

27. Electronic supplementary Table 5. continued
Organism (number tested)
and antimicrobial agent
MIC (μg/mL) %
MIC 50
MIC 90
Susceptible
Intermediate
Resistant
B. fragilis group (69)
SBT/ABPC 4 16 ―
TAZ/PIPC* 8 32
TAZ/PIPC** 2
95.7%
0.0%
4.3%
CMZ 64
50.7%
17.4%
31.9%
CFX
128
65.2%
18.9%
15.9%
FMOX
MEPM
0.25
94.2%
5.8%
CPFX
LVFX
MFLX
55.1%
29.0%
STFX
0.125
CLDM
≥256
44.9%
1.5%
53.6%
TGC
MNZ 1
100.0%
*: concentration of TAZ was changed according to the concentration ratio of 1 : 8; **: a fixed concentration of 4 µg/mL TAZ was used